Biopharma MEA, Win the “2014, Distributor of The Year Award” from Gilead Sciences

Biopharma MEA, Win the “2014, Distributor of The Year Award” from Gilead Sciences

BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome

FDA approves Vimizim to treat rare congenital enzyme disorder  First drug to receive Rare Pediatric Disease Priority Review Voucher The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease caused by a [...]

FDA APPROVES SOVALDI

FDA approves Sovaldi for chronic hepatitis C Drug is third with breakthrough therapy designation to receive FDA approval   The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection [...]

ELITE meeting

With the outstanding success of Elite I meeting in Hamburg held in November  2013, BIOPharma-MEA is thankful for Medac sponsoring this standalone meeting that was really a great event.  

Successful BOARD IV meeting

LG life sciences sponsors the forth BOARD meeting for IVF specialists in the region at Gold Coast – Australia 4th – 8th October 2013